Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 3 5 W DEXTROSE 25 IN PLASTIC CONTAINER versus AMINOSYN 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN 3 5 W DEXTROSE 25 IN PLASTIC CONTAINER versus AMINOSYN 5.
AMINOSYN 3.5% W/ DEXTROSE 25% IN PLASTIC CONTAINER vs AMINOSYN 5%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn 3.5% with dextrose 25% provides amino acids for protein synthesis and dextrose as a carbohydrate calorie source, primarily to prevent protein catabolism and maintain nitrogen balance in patients requiring parenteral nutrition.
Aminosyn 5% provides essential and nonessential amino acids for protein synthesis, maintaining nitrogen balance, and supporting tissue repair in patients unable to tolerate oral intake.
Intravenous infusion: 500 mL to 1000 mL per day, typically at a rate not exceeding 3 mL/kg/hour. Adjusted based on metabolic needs and fluid status.
Intravenous infusion; 500 mL of 5% solution (25 g protein equivalent) per day, typically at a rate not exceeding 100 mL/hour. Dosage individualized based on protein requirements and metabolic status.
None Documented
None Documented
Amino acids: 0.5-2 hours (plasma clearance). Dextrose: 1.5-2 hours (glucose half-life in normoglycemic patients); clinically, infusion must be continuous to maintain steady state.
Not applicable as a drug; amino acids have rapid turnover with half-lives varying from minutes to hours depending on the individual amino acid.
Renal excretion of amino acids and dextrose metabolites; urea nitrogen accounts for ~80% of nitrogen elimination. Biliary/fecal elimination is negligible for intact components.
Amino acids are metabolized; nitrogen is excreted renally as urea (80-90%) and in feces (5-10%).
Category C
Category C
Amino Acid Solution
Amino Acid Solution